Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin is a phase 2, randomised interventional study registered as NCT06698965 by Shanghai Chest Hospital, with a registry enrolment figure of 52 participants, started 2024-10-13 and due to reach its primary completion in 2029-10-31. Interventions recorded: Chemotherapy （Etoposide and Carboplatin）; Immunotherapy （Envafolimab）; Trilaciclib. Conditions listed: Lung Cancer, Small Cell. Primary outcome: The incidence of grade ≥ 3 neutropenia during chemotherapy treatment. Lung eligibility wording from the registry: "* Small cell lung cancer (SCLC) confirmed by histology or cytology;". Sites: China. No results are recorded here; the registry entry is the source.